PHILADELPHIA: A new four-year research study to determine the value of beta-amyloid imaging in diagnosing and treating Alzheimer’s disease and other dementias is ready to be launched. The study participants will be placed into either a subgroup for progressive, unexplained mild cognitive impairment or a subgroup for dementia of uncertain cause.
The study has two goals. The first goal is to assess the impact that amyloid PET imaging has on the short-term management of patients who meet the appropriate use criteria. Changes in management include patients using Alzheimer’s or other drug therapy and receiving counseling about safety and future planning earlier. The study will also compare patients enrolled in the study to a cohort of patients who have never undergone amyloid PET imaging to see whether the patients who underwent imaging have fewer hospitalizations and emergency room visits…